Table 1.
Patient and tumor characteristics by region
| Characteristic | Region |
||||
|---|---|---|---|---|---|
| Lampang | Penang | Singapore | Yogyakarta | Total | |
| Cases, n (row %) | 994 (29.1) | 417 (12.2) | 1338 (39.2) | 664 (19.5) | 3413 |
| Year of diagnosis, n (%) | |||||
| 2017 | 334 (33.6) | 157 (37.6) | 496 (37.1) | 187 (28.2) | 1174 (34.4) |
| 2018 | 362 (36.4) | 142 (34.1) | 420 (31.4) | 266 (40.1) | 1190 (34.9) |
| 2019 | 298 (30.0) | 118 (28.3) | 422 (31.5) | 211 (31.8) | 1049 (30.7) |
| Sex, n (%) | |||||
| Females | 375 (37.7) | 153 (36.7) | 538 (40.2) | 243 (36.6) | 1309 (38.4) |
| Males | 619 (62.3) | 264 (63.3) | 800 (59.8) | 421 (63.4) | 2104 (61.6) |
| Age at diagnosis, years, n (%) | |||||
| <55 years | 115 (11.6) | 80 (19.2) | 181 (13.5) | 179 (27.0) | 555 (16.3) |
| 55-64 | 265 (26.7) | 116 (27.8) | 359 (26.8) | 216 (32.5) | 956 (28.0) |
| 65-74 | 324 (32.6) | 137 (32.9) | 478 (35.7) | 167 (25.2) | 1106 (32.4) |
| 75-84 | 233 (23.4) | 74 (17.7) | 291 (21.7) | 89 (13.4) | 687 (20.1) |
| 85+ | 57 (5.7) | 10 (2.4) | 29 (2.2) | 13 (2.0) | 109 (3.2) |
| Median age at diagnosis (range) | 68 (25-97) | 65 (23-93) | 67 (19-93) | 62 (20-94) | 66 (19-97) |
| Smoking history, n (%) | |||||
| Current | 135 (13.6) | 91 (21.8) | 419 (31.3) | 69 (10.4) | 714 (20.9) |
| Ever | 405 (40.7) | 138 (33.1) | 250 (18.7) | 143 (21.5) | 936 (27.4) |
| Never | 363 (36.5) | 180 (43.2) | 669 (50.0) | 145 (21.8) | 1357 (39.8) |
| Unknown | 91 (9.2) | 8 (1.9) | 0 (0) | 307 (46.2) | 406 (11.9) |
| Basis of diagnosis, n (%) | |||||
| Histology | 531 (53.4) | 382 (91.6) | 1175 (87.8) | 76 (11.4) | 2164 (63.4) |
| Cytology | 97 (9.8) | 4 (1.0) | 152 (11.4) | 535 (80.6) | 788 (23.1) |
| Imaging | 335 (33.7) | 18 (4.3) | 5 (0.4) | 34 (5.1) | 392 (11.5) |
| Clinical | 31 (3.1) | 13 (3.1) | 2 (0.1) | 19 (2.9) | 65 (1.9) |
| Death certificate only | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Unknown | 0 (0) | 0 (0) | 4 (0.3) | 0 (0) | 4 (0.1) |
| Pathological diagnosis, n (%) | |||||
| Small-cell lung cancer | 38 (3.8) | 16 (3.8) | 83 (6.2) | 31 (4.7) | 168 (4.9) |
| Non-small-cell lung cancer | 558 (56.1) | 337 (80.8) | 1242 (92.8) | 571 (86.0) | 2708 (79.3) |
| Squamous cell carcinoma | 85 (8.6) | 63 (15.1) | 164 (12.3) | 151 (22.7) | 463 (13.6) |
| Non-squamous cell carcinoma | |||||
| Adenocarcinoma | 416 (41.9) | 247 (59.2) | 957 (71.5) | 367 (55.3) | 1,987 (58.2) |
| Large cell carcinoma | 3 (0.3) | 7 (1.7) | 0 (0) | 4 (0.6) | 14 (0.4) |
| Non-small-cell lung cancer, NOS | 54 (5.4) | 20 (4.8) | 121 (9.0) | 49 (7.4) | 244 (7.1) |
| Other | 32 (3.2) | 33 (7.9) | 7 (0.5) | 14 (2.1) | 86 (2.5) |
| Lung cancer without a pathological diagnosis | 366 (36.8) | 31 (7.4) | 6 (0.4) | 48 (7.2) | 451 (13.2) |
| Stage, grouped TNM, n (%) | |||||
| Stage I | 32 (3.2) | 20 (4.8) | 273 (20.4) | 0 (0) | 325 (9.5) |
| Stage II | 20 (2.0) | 16 (3.8) | 86 (6.4) | 9 (1.4) | 131 (3.8) |
| Stage III | 129 (13.0) | 89 (21.3) | 200 (14.9) | 27 (4.1) | 445 (13.0) |
| Stage IV | 735 (73.9) | 266 (63.8) | 764 (57.1) | 476 (71.7) | 2,241 (65.7) |
| Unknown | 78 (7.8) | 26 (6.2) | 15 (1.1) | 152 (22.9) | 271 (7.9) |
| ECOG performance status, n (%) | |||||
| 0 | 20 (2.0) | 58 (13.9) | 525 (39.2) | 19 (2.9) | 622 (18.2) |
| 1 | 427 (43.0) | 98 (23.5) | 639 (47.8) | 84 (12.7) | 1,248 (36.6) |
| 2 | 387 (38.9) | 108 (25.9) | 112 (8.4) | 157 (23.6) | 764 (22.4) |
| 3 | 113 (11.4) | 106 (25.4) | 42 (3.1) | 215 (32.4) | 476 (13.9) |
| 4 | 7 (0.7) | 27 (6.5) | 6 (0.4) | 72 (10.8) | 112 (3.3) |
| 5 | 4 (0.4) | 3 (0.7) | 0 (0) | 0 (0) | 7 (0.2) |
| Unknown | 36 (3.6) | 17 (4.1) | 14 (1.0) | 117 (17.6) | 184 (5.4) |
ECOG, Eastern Cooperative Oncology Group; NOS, not otherwise specified; TNM, tumor–node–metastasis.